Bio-Techne Corp (TE1.SG) Seasonal returns chart
The article presents a seasonal returns chart for Bio-Techne Corp (TE1.SG), displaying the average monthly price return between 2016 and 2026. This chart allows investors to view the stock's performance trends over various timeframes, including 3Y, 5Y, 10Y, 20Y, and all available data. The current stock price for Bio-Techne Corp is 66.04 EUR, reflecting a slight decrease of 0.12% as of the last market open.
Is Bio Techne (TECH) Fully Valued On Its Latest Earnings And Merck Linked Dividend?
Bio-Techne (TECH) recently reported first-quarter results with sales of US$299.71 million and net income of US$28.29 million, along with a US$0.08 quarterly dividend related to its Merck KGaA transaction. The stock has seen significant year-to-date and annual returns, but Simply Wall St's analyst consensus suggests it is modestly overvalued with a fair value estimate of $70.73 compared to its recent close of $72.84. Investors are weighing the softer quarterly earnings against steady sales and the potential benefits of the Merck deal and recurring revenue from consumables.
Bio-Techne (TECH) corrects electronic signatures; quarterly results remain unchanged.
Bio-Techne (TECH) filed an amended quarterly report (10-Q/A) to correct omitted conformed electronic signatures, with no other changes to the financial results. The company reported quarterly net sales of $299.7 million, a 5% increase year-over-year, while GAAP net earnings decreased to $28.3 million from $38.2 million. The amendment confirms that the previously released financial figures remain accurate.
Mdxhealth Reports Third Quarter 2026 Financial Results
MDxHealth SA reported flat revenue of $22.7 million for the third quarter of 2026 compared to the prior year, with an increased operating loss of $8.1 million and a net loss of $12.3 million. The company's CEO, Michael K. McGarrity, attributed the results to a temporary disruption in commercial execution due to sales organization turnover and outlined a restructuring plan to refocus sales and marketing, aiming for a return to growth in 2027. Key highlights include an 11% decrease in tissue-based test volume and increased liquid-based test volume, alongside a strategic discontinuation of the Resolve mdx business.
StoneX reiterates Hold on Bio-Techne stock as Merck deal nears
StoneX has reiterated a Hold rating on Bio-Techne Corp. as the company's acquisition by Merck KGaA approaches. Bio-Techne reported a 4.6% revenue growth in Q1 fiscal 2027 and a 54% gain in shares over the past six months, though InvestingPro data suggests the stock is overvalued. The merger is expected to close by late 2026 or early 2027.
Century Therapeutics advances diabetes and autoimmune therapies, targets clinical trials in 2026-27 with strong cash runway.
Century Therapeutics reported progress on its iPSC-derived therapies for type 1 diabetes and autoimmune diseases, planning an IND submission for CNTY-813 by Q4 2026 and clinical trials for CNTY-308 in 2026. The company holds $174.1 million in cash, providing a runway into early 2029 to support these upcoming clinical milestones. This update comes amidst a fluctuating health sector market, with Century well-positioned to advance its therapeutic pipeline.
Twist Bioscience Corporation (TWST) Tops Q4 EPS by 6c, Offers Guidance
Twist Bioscience Corporation (TWST) reported Q4 EPS of ($0.32), exceeding analyst estimates by $0.06, with revenue also surpassing consensus expectations at $126.6 million. The company provided Q1 2027 revenue guidance of $130-132 million and FY2027 revenue guidance of $550-560 million, both above current consensus estimates, alongside a gross margin forecast of approximately 52.5% to 53%.
Merck KGaA raises 2026 outlook as Bio-Techne deal nears completion
Merck KGaA reported its Q3 2026 results and has raised its full-year guidance for the third time this year. This positive outlook comes as the German conglomerate is nearing completion of its $11.3 billion acquisition of U.S. life sciences firm Bio-Techne.
Mettler-Toledo International Inc. (NYSE:MTD) Released Earnings Last Week And Analysts Lifted Their Price Target To US$1,674
Mettler-Toledo International Inc. (NYSE:MTD) reported strong earnings last week, with revenues exceeding analyst predictions and statutory earnings per share also beating expectations. Following these results, analysts have updated their models, becoming more bullish on the business and lifting their consensus price target to US$1,674, a 9.7% increase. The company is also expected to accelerate its growth, though at a slower pace than the industry average.
TECH Q1 Earnings & Revenues Beat, Merck KGaA Merger Deal Advances
Bio-Techne Corporation (TECH) reported strong first-quarter fiscal 2027 results, surpassing Zacks Consensus Estimates for both adjusted earnings per share and net sales. The company also announced that its shareholders have approved the merger agreement with Merck KGaA, an important step towards the completion of the $11.3 billion acquisition expected by late 2026 or early 2027. This merger aims to strengthen their global presence and service capabilities across the life sciences value chain.
TECH Q1 Earnings & Revenues Beat, Merck KGaA Merger Deal Advances
Bio-Techne Corporation (TECH) reported strong first-quarter fiscal 2027 results, surpassing Zacks Consensus Estimates for both earnings and revenues. The company announced adjusted EPS of 44 cents, up 4.8% year-over-year, and net sales of $299.7 million, an increase of 5%. Additionally, Bio-Techne shareholders approved the merger agreement with Merck KGaA, with the transaction expected to close by late 2026 or early 2027.
What Bio-Techne Doubters Overlooked
Bio-Techne's stock delivered a 27.5% return over the past year, surprising doubters who questioned the durability of its recurring revenue. The company's Q4 2026 report showed a significant shift to profitability, with a 17.0% net margin, supporting a more optimistic view of its business built on life science consumables and platforms. However, the current stock price of US$72.78 already reflects a positive outlook, suggesting that future gains depend on successful integration of Merck and sustained growth in proteomic and cell therapy tools.
Bio-Techne 3Q 2026: Revenue $299.71M, EPS $0.18 — 10-Q Summary
Bio-Techne reported its first-quarter fiscal 2027 net sales increased 5% year over year to $299.71 million, while net earnings declined by 25.9% to $28.29 million, resulting in a diluted EPS of $0.18. The company saw organic revenue growth of 7%, but lower segment operating margins in Diagnostics and Spatial Biology, along with increased SG&A and R&D expenses, impacted results. Bio-Techne anticipates approximately $28 million in capital expenditures for the remainder of fiscal 2027 to support expected sales growth.
Sales rise 5% at Bio-Techne (TECH), but quarterly earnings move the other way.
Bio-Techne (TECH) reported a 5% increase in net sales to $299.712 million for Q1 fiscal 2027, up from $286.555 million in the prior year. Despite rising sales, net earnings declined to $28.293 million from $38.185 million, and operating income fell to $36.603 million from $47.658 million. The company's cash from operations, however, significantly increased to $73.113 million, attributed primarily to the timing of cash payments on operating assets and liabilities.
FMR LLC and Abigail P. Johnson Report 0.7% Stake in Bio-Techne Corp via 13G Amendment
FMR LLC and Abigail P. Johnson have filed an Amendment No. 2 to their Schedule 13G, disclosing a beneficial ownership of 1,088,114.27 shares, representing 0.7% of Bio-Techne Corp's outstanding common stock. This filing, made on November 4, 2026, details their sole voting and dispositive powers over the shares as of September 30, 2026, confirming the acquisition was for ordinary business purposes. The disclosure highlights their significant, non-controlling stake in Bio-Techne Corp (NASDAQ:TECH).
BIO-TECHNE DECLARES DIVIDEND
Bio-Techne's Board of Directors has declared a quarterly dividend of $0.08 per share for the quarter ended September 30, 2026. This dividend is payable on November 23, 2026, to shareholders of record on November 13, 2026, provided that the pending transaction with Merck KGaA has not closed by that date. Future dividends will be considered on a quarterly basis.
Bio-Techne (TECH) Stock Trades Above Fair Value On Cash Flow Estimates
Bio-Techne's stock (TECH) is currently trading above its estimated intrinsic value based on a Discounted Cash Flow (DCF) model, despite delivering positive returns over the past year. The DCF analysis suggests the company's future cash flows do not fully support the current share price of $72.66. The article highlights both bull and bear narratives from the Simply Wall St Community, with some finding it roughly fairly valued due to growth in spatial biology, and others seeing it as 28% overvalued, potentially reflecting a takeover premium.
Bio-Techne earnings missed by $0.03, revenue fell short of estimates
Bio-Techne (NASDAQ: TECH) reported third-quarter earnings per share (EPS) of $0.42, missing the analyst estimate of $0.45 by $0.03. Revenue for the quarter was $292.7 million, falling short of the consensus estimate of $293.03 million. Despite the miss, Bio-Techne's stock has seen positive performance over the last 3 and 12 months, with a "good performance" financial health score according to InvestingPro.
BIO-TECHNE DECLARES DIVIDEND
Bio-Techne's Board of Directors has declared a quarterly dividend of $0.08 per share for the quarter ending September 30, 2026. This dividend is payable on November 23, 2026, to shareholders of record on November 13, 2026, provided that the pending transaction with Merck KGaA has not closed by that date. Future dividends will be subject to quarterly review by the Board.
Bio-Techne declares $0.08 quarterly dividend, pending Merck acquisition closure by Nov 13, 2026.
Bio-Techne Corporation announced a quarterly dividend of $0.08 per share, payable on November 23, 2026, contingent on its acquisition by Merck KGaA not closing by November 13, 2026. The company, a global life sciences firm with over $1.2 billion in fiscal 2026 sales, trades near its 52-week high with a modest dividend yield of 0.44% and a market cap of $11.41 billion. Investor sentiment appears cautious, with full sell-side order activity.
Bio-Techne Corporation (TECH) Declares $0.08 Quarterly Dividend
Bio-Techne Corporation (TECH) has declared a $0.08-per-share dividend for the quarter ended September 30, 2026. This dividend is payable on November 23 to shareholders of record on November 13, but is conditional on its pending Merck transaction not closing by the record date. The closing of the Merck transaction by November 13 will determine eligibility for the dividend payment.
Bio-Techne shareholders get $0.08 only if its Merck deal hasn't closed by Nov. 13.
Bio-Techne (NASDAQ: TECH) has declared a conditional quarterly dividend of $0.08 per share, payable on November 23, 2026. This dividend is for common shareholders of record by November 13, 2026, and is contingent upon the previously announced transaction with Merck KGaA not closing on or before that date. Future cash dividends will be considered quarterly by the Board of Directors.
At $72.66 per share, Bio-Techne (TECH) CEO delivers or withholds 2,385 shares.
Bio-Techne's CEO, Kim Kelderman, delivered or withheld 2,385 common shares on November 1, 2026, for tax liability or exercise price payment, valued at $72.66 per share. Following this transaction, Kelderman's direct common-stock holding is 80,509 shares. The CEO also holds direct options for 90,441 common shares with a $53.60 exercise price, set to expire on August 15, 2035, along with various restricted stock units vesting on future dates.
Stock awards vest for Bio-Techne (TECH) CFO James Hippel, yielding 11,545 shares.
Bio-Techne's CFO, James Hippel, acquired 11,545 common shares after restricted stock units vested on November 1, 2026. On the same date, 5,096 shares were withheld for tax liability. His holdings now include 176,720 common shares, 84,259 restricted stock unit contracts, 371,927 stock option contracts, and 53,482 performance restricted stock unit contracts.
BIO-TECHNE DECLARES DIVIDEND
Bio-Techne Corporation (NASDAQ: TECH) announced a quarterly dividend of $0.08 per share for the quarter ended September 30, 2026. The dividend is payable on November 23, 2026, to shareholders of record by November 13, 2026, provided its transaction with Merck KGaA has not closed by that date. The company, a global life sciences firm, stated that future cash dividends would be considered quarterly by its Board of Directors.
Form 4 Bio-Techne Corp: James Hippel (CFO) For: 15 August By Investing.com
This article reports on a Form 4 filing for Bio-Techne Corp, specifically concerning James Hippel, the CFO. The filing date mentioned is August 15. The content is brief, primarily serving as an announcement of the financial disclosure.
Form 4 Bio-Techne Corp: James Hippel (CFO) For: 15 August
This article reports on a Form 4 filing for Bio-Techne Corp, indicating a transaction involving James Hippel, the company's CFO, for August 15. Form 4 filings are regulatory documents detailing changes in beneficial ownership of company stock by insiders. The article provides only this essential information without further details on the nature of the transaction.
CFO reports forfeiture of 34,443 performance stock options at BIO-TECHNE (TECH).
BIO-TECHNE (TECH) CFO James Hippel reported transactions on August 15, 2026, which included the conversion of restricted stock units into 9,980 common shares and the forfeiture of 34,443 performance stock options and 12,798 performance RSUs. The Board of Directors authorized discretionary vesting for 2,871 performance options and 1,067 performance RSUs. Additionally, 4,423 shares were delivered or withheld for tax liability at $72.40 per share.
An executive acquires 6,547 Bio-Techne (TECH) shares and delivers or withholds 2,019 for payment.
William Geist, President of Protein Sciences at Bio-Techne (TECH), reported recent direct transactions including the disposition of 22,545 performance stock options and the acquisition of 6,547 common shares. The filing also details the delivery or withholding of 2,019 shares for payment of exercise price or tax liability, with additional RSU transactions and future vesting dates through August 2028. This Form 4/A filing amends a previous report, clarifying the insider trading activity.
The CEO of BIO-TECHNE (TECH) reports 10,955 shares delivered or withheld for exercise costs or taxes.
BIO-TECHNE (TECH) CEO Kim Kelderman reported equity-award transactions on August 15, 2026, including the acquisition of 21,736 common shares. Additionally, 10,955 shares were delivered or withheld for payment of exercise price or tax liability at $72.40 per share. The report also detailed dispositions and discretionary vesting of various performance stock options and restricted stock units.
Form 4 BIO-TECHNE Corp For: Oct 29 Filed by: Klimovsky Judith V.
This article details a Form 4 filing for BIO-TECHNE Corp (TECH) by Judith V. Klimovsky, a director, on October 29, 2026. The filing indicates the acquisition of 2,750 shares of common stock at $0, bringing her direct beneficial ownership to 6,532 shares. It also lists several stock options held by Klimovsky with varying exercise prices and expiration dates.
Bio-Techne (TECH) Stock Forecast & Analyst Ratings
This article provides a stock forecast and analyst ratings for Bio-Techne (TECH). It details the company's financial health, recent performance, and future outlook based on expert analysis, offering insights into its investment potential.
Bio-Techne Corp (TE1.DU) Seasonal returns chart
The article presents a seasonal returns chart for Bio-Techne Corp (TE1.DU) based on historical data. It displays the average monthly price return for various periods, including 3Y, 5Y, 10Y, 20Y, and all available data. The current quote for Bio-Techne Corp on the Dusseldorf exchange is 64.54 EUR, showing a slight decrease.
How Bio-techne Corp (TECH) Affects Rotational Strategy Timing
Bio-techne Corp (NASDAQ: TECH) shows neutral near and mid-term readings, potentially moderating a long-term positive bias, with a mid-channel oscillation pattern in play. The article details three institutional trading strategies (Position, Momentum Breakout, and Risk Hedging) and provides multi-timeframe signal analysis, including specific support and resistance levels. An exceptional 36.2:1 risk-reward setup targeting a 10.4% gain versus 0.3% risk is highlighted.
Bio-Techne Corporation (TECH) Seasonal returns chart
This article provides a historical seasonality chart for Bio-Techne Corporation (TECH), showing average monthly price returns from 2016 to 2026. It includes current stock information, indicating a closing price of $72.66 with a slight decrease of 0.07%. The page is primarily a data visualization for stock performance trends.
Charles River Laboratories International Inc. Stock Grades | CRL
This article provides detailed stock information for Charles River Laboratories International Inc. (CRL), including its current market performance, analyst ratings, and key financial metrics. It shows the company's stock is trading at $0.00, with a significant YTD and 12-month change, and features an average analyst price target of $331.29, with an "Under Hold Over Buy" score. The company's profile highlights its focus on providing products and services to pharmaceutical and biotechnology companies across its Research Models and Services, Discovery and Safety Assessment, and Manufacturing Solutions segments.
Form 10-K/A BIO-TECHNE Corp For: Jun 30
BIO-TECHNE Corporation has filed an Amendment No. 1 to its Annual Report on Form 10-K for the fiscal year ended June 30, 2026. This amendment, filed as Form 10-K/A, primarily includes information related to Part III of Form 10-K concerning directors, executive compensation, security ownership, and related transactions, which was not included in the original report. The filing also details the impact of a proposed merger with Merck KGaA, including the treatment of equity awards and retention bonuses for named executive officers.
Five executives are approved for conditional retention cash at Bio-Techne (TECH).
Bio-Techne (TECH) has approved conditional cash retention awards totaling over $6.6 million for five named executive officers, including CEO Kim Kelderman ($2.12 million) and President Steven Crouse ($910,263). These awards, tied to a contemplated merger with Merck KGaA, are designed to incentivize executives to remain with the company through the merger's effective date or agreement termination, subject to employment conditions and a release of claims. The company also detailed its executive compensation program, including base salaries, annual cash bonuses, and long-term equity awards, and disclosed the payouts for fiscal year 2024–2026 performance awards, which resulted in 0% for revenue and adjusted EBITA targets but 50% for relative total shareholder return.
Loews Corporation (L) Stock forecasts
An Argus analyst has upgraded Loews Corporation (L) stock to a BUY rating as of October 21, 2026. The current price is $111.04, and Loews Corp is described as a holding company with subsidiaries in insurance, natural gas transportation, hotels, and plastic packaging.
Bio-Techne Corp (TECH) Stock forecasts
Argus has lowered its rating for Bio-Techne Corporation (TECH) to SELL, citing the company's development and marketing of protein-based instruments and reagents for research and clinical use. The company serves pharmaceutical and biotech industries, as well as academic institutions. The current price is $72.69.
Bio-Techne Corp (TECH) Stock forecasts
The article provides a market update with major indices showing gains at midday due to ongoing earnings reports. Key tech companies like Alphabet, Amazon, and Microsoft are highlighted, along with rising crude oil prices and a falling yield on the 10-year note. It also includes related analyst reports and a brief overview of current market performance for various global indices and cryptocurrencies.
Gaming and Leisure Properties, (GLPI) Stock forecasts
Argus has raised its target price for Gaming and Leisure Properties Inc (GLPI) to $37.00. The company is a self-administered and self-managed Pennsylvania real estate investment trust (REIT). The current price of GLPI stock is $39.39.
Bio-Techne Corp Estimates – NASDAQ:TECH
This page on TradingView provides financial actuals and analyst estimates for Bio-Techne Corp (NASDAQ: TECH). It allows users to explore reported financial data across income statements, balance sheets, cash flow statements, and valuation metrics. Users can compare actual results with average, high, and low estimates and visualize trends over time for both annual and quarterly periods.
Bio-Techne Corporation Estimates – SWB:TE1
This page provides financial estimates for Bio-Techne Corporation (SWB:TE1), listed on the Stuttgart Stock Exchange. It offers an overview of reported financial data and analyst estimates across various financial statements and valuation metrics. Users can compare actual results with average, high, and low estimates and visualize trends over time, although it includes a disclaimer that this is not investment advice.
17 analysts give Bio-Techne stock a USD 68.92 average target
Seventeen analysts have set an average 12-month target of USD 68.92 for Bio-Techne stock, with a consensus "Hold" rating. The company reported fiscal 2026 revenue of USD 1.22 billion and an adjusted operating margin of 32.20 percent. Despite trading near its yearly high, the stock's current market price of USD 72.58 is 5.04 percent above the analyst consensus target, leading to a focus on valuation rather than sales acceleration.
Bio-Techne stock has a November 4, 2026 reporting date
Bio-Techne (ISIN US09073M1045) is scheduled to release its next quarterly report on November 4, 2026, with an estimated revenue of USD 292.61 million for the upcoming quarter. The stock's last recorded price was EUR 64.57 on October 16, 2026, and its P/E ratio stands at 62.56. Investors will compare the upcoming figures against the fiscal year 2026 results, which showed USD 321.2 million in revenue and an adjusted gross margin of 69.2 percent.
Invesco S&P 500 Equal Weight ETF (RSP) Stock Price, Holdings, Dividend Yield
This article provides a detailed overview of the Invesco S&P 500 Equal Weight ETF (RSP), including its current stock price, key financial ratios like PE and PB, dividend yield, and top holdings as of its latest N-PORT filing. It highlights that the ETF holds 504 stocks with a total value of $96.73 billion and lists the top five holdings: PayPal, Bio-Techne, Zebra Technologies, Global Payments, and Expedia. The article also presents performance metrics, key statistics, fundamental data, and historical trends for the ETF.
Bio-Techne stock sits 0.22 percent below its 52-week high
Bio-Techne's stock is currently trading just 0.22 percent below its 52-week high at EUR 64.71, with analysts maintaining a cautious "Hold" consensus and a target price slightly below its current trading price. The company recently announced the expansion of its manufacturing network and is scheduled to release its next earnings report on November 3, 2026. Despite trading near its yearly high, trading volume was significantly lower than average.
Incyte Corp. Company & People | INCY
This page provides a comprehensive overview of Incyte Corp. (INCY), a biopharmaceutical company focused on hematology, oncology, inflammation, and autoimmunity. It includes real-time stock data, analyst ratings, key financial metrics, company details, executive information, and various valuation and profitability ratios. The company was founded on April 8, 1991, and is headquartered in Wilmington, DE.
Vir Biotechnology (NasdaqGS:VIR) Stock Price
This article provides an overview of Vir Biotechnology (NasdaqGS:VIR) stock performance, analyst targets, and recent news. It highlights the company's valuation, clinical advancements in oncology and hepatitis delta, and the recent FDA Fast Track designation for VIR-5500 for prostate cancer, along with a key executive appointment.